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Abstract 
 
Purpose: Since chemo-radiotherapy selectively targets proliferating cancer cells, quiescent 
cancer stem-like (CS-like) cells are resistant. Mobilization of cell cycle in quiescent leukemia 
stem cells sensitizes them to cell death signals. However, it is unclear that mobilization of cell 
cycle can eliminate quiescent CS-like cells in solid cancers. Thus, we explored the use of a 
genetically engineered telomerase-specific oncolytic adenovirus, OBP-301 to mobilize the 
cell cycle and kill quiescent CS-like cells. 
Experimental design: We established CD133+ CS-like cells from human gastric cancer 
MKN45 and MKN7 cells. We investigated the efficacy of OBP-301 against quiescent CS-like 
cells. We visualized the treatment dynamics that OBP-301 killed quiescent CS-like cells in 
dormant tumor spheres and xenografts using fluorescent ubiquitination cell cycle indicator 
(FUCCI). 
Results: CD133+ gastric cancer cells had stemness properties. OBP-301 efficiently killed 
CD133+ CS-like cells resistant to chemo-radiotherapy. OBP-301 induced cell cycle 
mobilization from G0/G1 to S/G2/M phase and subsequent cell death in quiescent CD133+ 
CS-like cells by mobilizing cell-cycle related proteins. FUCCI enabled visualization of 
quiescent CD133+ CS-like cells and proliferating CD133- non CS-like cells. 
Three-dimensional visualization of the cell cycle behavior in tumor spheres showed that 
CD133+ CS-like cells maintained stemness by remaining in G0/G1 phase. We demonstrated 
that OBP-301 mobilized quiescent CS-like cells in tumor spheres and xenografts into S/G2/M 
phases where they lost viability and CS-like cell property, and became chemosensitive. 
Conclusion: Oncolytic adenoviral infection is an effective mechanism of cancer cell killing 
in solid cancer and can be a new therapeutic paradigm to eliminate quiescent CS-like cells. 
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Translational Relevance 
 
Current chemotherapy and radiotherapy target proliferating cancer cells, while having 
little effect on dormant cancer cells. Cancer stem-like (CS-like) cells can maintain a quiescent 
or dormant state, which contributes largely to their resistance to conventional therapies. 
Recently, several therapeutic strategies have targeted inhibition of quiescent state in leukemia 
stem cells. However, it is still unclear whether CS-like cells in solid tumors can also be 
eliminated by inhibition of their dormant state. Here, we show that a telomerase-specific 
adenovirus, OBP-301, mobilizes quiescent CS-like cells to cycle and lethally traps them into 
S-phase. Moreover, we demonstrated a spatiotemporal treatment dynamics that OBP-301 
decoyed quiescent CS-like cells in tumor spheres and xenografts into S-phase trap where they 
lost viability and CS-like cell property and become chemosensitive. Thus, our data provides 
that cell-cycle mobilization and S/G2/M-phase-trapping induced by adenoviral infection is an 
effective mechanism of cancer cell killing of CS-like cells in solid cancers. 
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Introduction 
 
Current cytotoxic chemo-radiotherapy selectively targets proliferating cancer cells. 
Quiescent or dormant cancer cells in contrast are often drug resistant and are a major 
impediment to cancer therapy (1, 2). Cancer stem-like (CS-like) cells or tumor-initiating cells 
(3-5) maintain a quiescent or dormant state, which appears to contribute to their resistance to 
conventional therapies (6-8). Recently, several therapeutic strategies have targeted inhibition 
of the CS-like cell quiescent state. For example, treatment with arsenic trioxide enhanced the 
sensitivity of Leukemia stem cells (LSCs) to cytosine arabinoside through inhibition of LCS 
quiescence (9). Acute myeloid leukemia stem cells can be induced to enter the cell cycle and 
apoptosis by treatment with granulocyte colony-stimulating factor (10). However, it is still 
unclear whether CS-like cells in solid tumors can also be eliminated by inducing them to 
cycle. 
Viruses can infect target cells, multiply, cause cell death and release viral particles. 
These features enable the use of viruses as anticancer agents that induce specific tumor lysis 
(11, 12). Adenoviral E1A, in particular, has been shown to exert tumor suppressive functions, 
including enhancement of chemoradiotherapy-induced apoptosis via inhibition of the cellular 
DNA repair machinery (13), and inhibition of cell proliferation via suppression of epidermal 
growth factor receptor (EGFR) (14) and HER2 (15). It has been recently reported that an 
oncolytic adenovirus efficiently eradicates CS-like cells as well as non-CS-like cells in brain 
tumors, breast cancer, and esophageal cancer (16-18). 
In the present study, we isolated CD133+ subpopulations from radioresistant cells in 
human gastric cancer cell lines and characterized them as CS-like cells. By using multicolor 
cell cycle imaging that color-codes the quiescent CS-like cells and proliferating non-CS-like 
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cells, we demonstrated the treatment dynamics that a genetically engineered 
telomerase-specific oncolytic adenovirus, OBP-301 (19, 20) eradicates dormant CD133+ 
CS-like cells via cell-cycle mobilization both in tumor spheres and in subcutaneous tumors. 
 
Materials and Methods 
 
Cell lines and radiation treatment. 
The human gastric cancer cell lines MKN45 and MKN7 were maintained according to the 
vendor’s specifications (21). Radioresistant MKN45 and MKN7 cells were established by 
administration of radiation treatments using an X-ray generator (MBR-1505R; Hitachi 
Medical Co.) 
 
Recombinant adenoviruses. 
The recombinant tumor-specific, replication-selective adenovirus vector OBP-301 
(Telomelysin), in which the promoter element of the human telomerase reverse transcriptase 
(hTERT) gene drives the expression of E1A and E1B genes linked to an internal ribosome 
entry site, was previously constructed and characterized (19, 22).  
 
Isolation of CD133+ and CD133- cells by flow cytometry. 
After incubated with an anti-CD133/2(293C)-Allophycocyanin antibody (Miltenyi Biotec), 
CD133+ cells were sorted by flow cytometry using FACSAria flow cytometer (Becton 
Dickinson). CD133+ and CD133− cells were separated by flow cytometry just before each 
experiment to ensure that the purity of the CD133+ population was greater than 70%, and the 
purity of CD133− cells was above 99%. 
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Cell viability assay. 
CD133+ and CD133− cells (5 × 102 cells/well) in 96-well plates were treated with OBP-301, 
cisplatin or radiation at the indicated doses. Cell viability was determined on day 5 after 
treatment using the Cell Proliferation Kit II (Roche Molecular) according to the 
manufacturer’s protocol. 
 
Establishment of MKN45 cells stably transfected with FUCCI vector plasmids.  
FUCCI (Fluorescent ubiquitination-based cell cycle indicator) system (23) was used to 
visualize the cell cycle phases. Plasmids expressing mKO2-hCdt1 (green fluorescence 
protein) or mAG-hGem (orange fluorescence protein) were obtained from the Medical & 
Biological Laboratory. Plasmids expressing mKO2-hCdt1 or mAG-hGem were transfected 
into radioresistant MKN45 cells using Lipofectamine LTX (Invitrogen). 
 
Western blot analysis.  
The primary antibodies used were: mouse anti-CD133/1(W6B3C) monoclonal antibody 
(mAb) (Miltenyi Biotec), rabbit anti-E2F1 polyclonal antibody (pAb) (Santa Cruz 
Biotechnology), mouse anti-Ad5 E1A mAb (BD Pharmingen), mouse anti-c-Myc pAb, rabbit 
anti-phospho-Akt mAb, rabbit anti-Akt mAb, mouse anti-p27 mAb (all three from Cell 
Signaling Technology), mouse anti-p53 mAb, mouse anti-p21 mAb (both from 
CALBIOCHEM Merck4 Biosciences), and mouse anti-β-actin mAb (Sigma-Aldrich). 
Immunoreactive bands on the blots were visualized using enhanced chemiluminescence 
substrates (ECL Plus; GE Healthcare). 
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Subcutaneous MKN45 tumor xenograft model. 
To evaluate a tumorigenicity of CD133+ and CD133− cells, purified CD133+ and CD133− 
cells in radioresistant MKN45 were inoculated at a density of 1 × 105 cells/site on the right 
and left sides, respectively, of the flank of 5-week-old female NOD/SCID mice (Charles 
River Laboratories) or athymic nude mice (Charles River Laboratories). To evaluate the in 
vivo antitumor effect of OBP-301, cisplatin or radiation, the radioresistant MKN45 cells were 
inoculated at a density of 5 × 106 cells/site into the flank of 5-week-old female athymic nude 
mice. OBP-301 (1 × 108 plaque forming units (PFU)) was injected into the tumors. Cisplatin 
(4 mg/body weight (kg)) was intraperitoneally injected and ionizing radiation (2 Gy) was 
performed into tumors after protection of normal tissues. Mice were treated every 3 days for a 
total of three treatments.  
 
Imaging of MKN45 cells expressing cell cycle-dependent fluorescent proteins. 
Time-lapse images of FUCCI expressing CD133+ and CD133− radioresistant MKN45 cells 
were acquired using a confocal laser scanning microscope (FV10i; Olympus). Cross-sections 
of FUCCI-expressing tumors were imaged using confocal laser scanning microscope 
(FV-1000; Olympus).  
 
Treatment of subcutaneous FUCCI-expressing MKN45 tumors. 
To evaluate the in vivo antitumor efficacy of OBP-301, cisplatin, paclitaxel or combination, 
the FUCCI-expressing MKN45 cells were inoculated at a density of 5 × 106 cells/site into the 
flank of 5-week-old female athymic nude mice (Charles River Laboratories). OBP-301 (1 × 
108 PFU/tumor) was injected into the tumors. Cisplatin (4 mg/kg) and paclitaxel (5 mg/kg) 
were injected intraperitoneally. Mice were treated every 3 days for a total of three to five 
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treatments. 
. 
Statistical analysis. 
Data are shown as means ± SD. For comparison between two groups, significant differences 
were determined using Student’s t-test. For comparison of more than two groups, statistical 
significance was determined with a one-way analysis of variance (ANOVA) followed by a 
Bonferroni multiple group comparison test. P values of < 0.05 were considered significant. 
 
Results 
 
CD133+ cells in human gastric cancer cells are cancer stem-like. 
CS-like cells are more resistant to radiotherapy than non-CS-like cells (24-26). To 
enrich CS-like subpopulations, we established radioresistant MKN45 and MKN7 human 
gastric cancer cells. Radioresistant MKN45 and MKN7 cells significantly had a higher 
percentage of CD133+ cells than parental cells (Fig. 1A and Supplementary Fig. S1A). We 
hypothesized that CD133 in gastric cancer would identify cancer cells with stem-like 
properties, such as asymmetric cell division, in vitro proliferation, dormancy, sphere 
formation, and in vivo tumorigenicity (5, 6). To investigate the asymmetric division of 
CD133+ cells, we determined if CD133+ cells produce both CD133+ and CD133− cells. 
CD133+ cells generated both CD133+ and CD133− cells, whereas CD133− cells could not 
produce CD133+ cells (Supplementary Fig. S2). We compared in vitro proliferation of 
CD133+ and CD133− cells. CD133+ cells produced larger colonies than CD133− cells. (Fig. 
1B and Supplementary Fig. S3). CD133+ cells made significantly much more tumor spheres 
than CD133− cells (Fig. 1B). CD133+ cells produced tumors in immunodeficient nude mice 
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and NOD/SCID mice, whereas CD133− cells did not generate any tumor in either nude on 
NOD/SCID mice (Supplementary Fig. S4 and Fig. 1B). Furthermore, CD133+ cells in 
radioresistant MKN45 and MKN7 cells were significantly more resistant to 5-fluorouracil, 
cisplatin, paclitaxel, and radiation than CD133− cells (Fig. 1C and Supplementary Fig. S1B). 
These data indicate that CD133+ cells are CS-like. 
 
Quiescent CD133+ CS-like cells and cycling CD133− non-CS-like cells are independently 
visualized by fluorescent cell cycle indicator technology 
Sakaue-Sawano et al. have reported that the cell cycle state in viable cells can be 
visualized using the fluorescent ubiquitination-based cell cycle indicator (FUCCI) system 
(23). We established FUCCI-expressing CD133+ or CD133− radioresistant MKN45 cells, in 
which cell nucleus at G0/ G1, S, or G2/M phase exhibit red, yellow, or green fluorescence, 
respectively. We compared the cell cycle phase of FUCCI-expressing CD133+ or CD133− 
cells. Time-lapse imaging showed that most of CD133+ cells were quiescent in G0/ G1 phase 
with red fluorescent nuclei compared with CD133− cells (Fig. 1D). Similar results were also 
observed in flow cytometry analysis of cell cycle (Supplementary Fig. S5A and S5B). 
CD133+ cells had similar proliferation rates as CD133− cells until 3 days after seeding. 
CD133+ cells showed lower proliferation rate than CD133− cells 5 days after seeding (Fig. 
1D). This result was consistent with the cell cycle status of CD133+ cells which had an 
increased percentage of cells in G0/ G1 phase. Moreover, we examined the cell cycle-related 
protein (27) expression in CD133+ and CD133− cells. CD133+ cells showed higher 
expressions of p53, p21 and p27 proteins compared with CD133− cells (Supplementary Fig. 
S8), suggesting that these proteins are involved in the maintenance of quiescent CS-like cells.  
 
Yano et al., Page 11 
OBP-301 efficiently kills CS-like cells with reducing CS-like cell frequency via enhanced 
viral replication. 
To evaluate the efficacy of OBP-301 against CD133+ CS-like cells, we treated 
CD133+ and CD133− cells from radioresistant MKN45 and MKN7 cells with OBP-301. 
OBP-301 similarly killed CD133+ and CD133− cells (Fig. 2A and Supplementary Fig. S1B). 
Next we investigated whether OBP-301 could decrease CS-like cell frequency. Flow 
cytometric analysis demonstrated OBP-301 significantly decreased the percentage of CD133+ 
cells compared with cisplatin or radiation (Fig. 2A). Expression of CD133 mRNA was 
closely associated with the population of CD133+ cells (Supplementary Fig. S6). OBP-301 
significantly suppressed the expression of CD133 mRNA compared with cisplatin and 
radiation (Supplementary Fig. S7). Western blot analysis also showed that cisplatin and 
radiation, but not OBP-301, increased three to fivefold CD133 expression in CD133+ cells 
(Fig. 2D). Moreover, pre-treatment of CD133+ cells with OBP-301, not cisplatin or radiation, 
significantly decreased the number of tumor spheres (Supplementary Fig. S13). These data 
indicated that OBP-301 kills both CD133+ and CD133− cells with reducing CS-like cell 
frequency. 
To further explore the efficacy of OBP-301 against CD133+ CS-like cell, we assessed 
the relationship between hTERT activity and viral replication. OBP-301 contains the hTERT 
promoter, which allows it to tumor-specifically regulate the gene expression of E1A and E1B 
for viral replication (19). Quantitative reverse transcriptation-polymerase chain reaction 
(qRT-PCR) showed that CD133+ cells had a significant, 3-fold higher expression of hTERT 
mRNA than CD133− cells (Fig. 2B), suggesting that CD133+ CS-like cells have a higher 
activity of hTERT than CD133− cells. Next we compared the expression of E1A mRNA and 
E1A protein in CD133+ cells and in CD133− cells. qRT-PCR showed that the expression of 
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E1A mRNA in CD133+ cells was higher than that in CD133− cells (Fig. 2B). Western blotting 
analysis showed that the expression of E1A in CD133+ cells was higher than that in CD133− 
cells (Fig. 2B). Furthermore we compared the copy number of the E1A gene, which is 
indicative of viral replication, in CD133+ and CD133− cells after infection with OBP-301. As 
expected, the copy number of the E1A gene in CD133+ cells was significantly higher than 
that in CD133− cells (Fig. 2B). These data indicate that OBP-301 is efficiently cytopathic for 
CD133+ cells due to the enhanced viral replication. 
 
OBP-301 mobilizes and lethally traps quiescent CS-like cells into S-phase in monolayer 
culture. 
To examine whether OBP-301 could change the cell cycle phase of quiescent CD133+ 
cells, we treated FUCCI-expressing CD133+ cells with OBP-301. Time-lapse imaging 
showed that OBP-301 infection significantly decreased the percentage of CD133+ cells in G0/ 
G1 phase, increased the percentage of CD133+ cells in S phase, and killed them at S-phase 
(Fig. 2C and Supplementary Movie S1). Similar results were also observed in flow cytometry 
analysis of cell cycle (Supplementary Fig. S5C and S5D). These results suggest that OBP-301 
induces cell cycle activation of quiescent CD133+ cells from G0/ G1 phase to S phase and 
kills them. We next assessed the molecular mechanism by which OBP-301 induces 
mobilization of cell cycle in quiescent CS-like cells. OBP-301 increased the expression of 
E2F1, c-Myc and phospho-Akt proteins that function as cell cycle accelerators (27) and 
decreased the expression of p53, p21 and p27 proteins that function as cell cycle brakes (27) 
in quiescent CD133+ cells (Fig. 2D). In contrast, cisplatin and radiation increased the 
expression of p53 and p21 proteins (Fig. 2D). We further examined whether adenoviral E1A 
altered the expression of these proteins in CD133+ cells. E1A-expressing OBP-301 and Ad5, 
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but not E1A-defficient dl312, similarly altered the expression of these proteins in CD133+ 
cells (Supplementary Fig. S9). These results indicate that OBP-301 induces cell cycle 
progression through upregulation of E2F-related proteins and downregulation of p53-related 
and p27 proteins by enhanced adenoviral E1A in quiescent CS-like cells. 
 
Three-dimensional tumor spheres maintain CD133+ subpopulation by keeping 
quiescent. 
Formation of tumor spheres under serum-free conditions is frequently used to 
maintain CS-like cell subpopulations (28). The addition of serum makes floating 
undifferentiated tumor spheres migrate from sphere to adherent cells and differentiate into 
adherent cells (29). Therefore, we hypothesized that tumor sphere maintained CS-like cell 
frequency due to be quiescent. CD133+ cells at each cell cycle in three-dimensional culture 
gathered, formed tumor spheres, and became in G0/G1 phase (Fig. 3A). Tumor spheres from 
CD133+ cells contained more quiescent cells than those from CD133− cells (Fig. 3B). 
Moreover, the established tumor spheres from CD133+ cells in three-dimensional culture 
without serum remained quiescence (Fig. 3C). In contrast, the established tumor spheres, 
after adding serum, exited from quiescent state and began to cycle, divide and increase (Fig. 
3C and Supplementary Movie S2). Flow cytometric analysis demonstrated that CD133+ cells 
could be maintained in tumor spheres cultured in serum-free medium for 2 weeks, whereas 
the percentage of CD133+ cells significantly decreased in CD133+ cells cultured in 
monolayer cultures or in tumor spheres cultured in serum-containing medium (Fig. 3D). 
These data indicate that tumor sphere maintains CSC frequency keeping dormant. 
 
Real-time imaging spatiotemporally shows OBP-301 eliminates dormant tumor spheres 
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by cell-cycle mobilization and S/G2/M-phase-trapping. 
 To further evaluate OBP-301 induced cell-cycle mobilization and S-phase-trapping in 
dormant tumor sphere, we visualized the treatment dynamics of FUCCI-expressing tumor 
spheres with OBP-301 infection. Time-lapse imaging demonstrated OBP-301 infected 
quiescent CD133+ cells at the periphery of the spheres and then induced S and G2/M phase 
entry, leading to the cellular death by viral replication (Fig. 4A). Moreover, as OBP-301 
penetrated into the deeper layers, tumor spheres gradually shrunk after virus infection (Fig. 
4A, 4C). In contrast, cisplatin and radiation did not affect the cell cycle phase or the size of 
tumor spheres (Figs. 4A, 4B, 4C and Supplementary Movie S3). Immunofluorescent staining 
of tumor spheres also confirmed that OBP-301 infection downregulated CD133, p53, and p21 
expression, and upregulated E2F1 and phospho-Akt expression in tumor spheres (Fig. 4D). 
These results suggest that OBP-301 efficiently eradicates dormant tumor sphere resistant to 
conventional therapies by mobilizing them into an S/G2/M-phase trap. 
 
OBP-301 efficiently kills dormant cancer stem-like cells in established human tumor 
xenografts by cell-cycle mobilization and S/G2/M-phase-trapping thereby reducing 
cancer stem-like cell frequency. 
To further confirm whether OBP-301 efficiently reduced CD133+ CS-like cell 
frequency within tumor tissues (Supplementary Figure S10A), we investigated the expression 
of CD133 mRNA and CD133 positive ratio in subcutaneous tumors derived from 
radioresistant MKN45 cells after treatment of OBP-301, cisplatin or irradiation. Suppression 
of tumor growth by OBP-301 (Fig. 5A) was accompanied by a significant decrease in CD133 
mRNA at 2 weeks after the final treatment (Fig. 5B). In contrast, although cisplatin and 
radiation also suppressed tumor growth to a similar extent as OBP-301 (Fig. 5A), cisplatin 
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did not affect, and radiation significantly increased CD133 mRNA expression at 1 week after 
the final treatment (Fig. 5B). Immunohistochemistry of CD133-stained tumor sections also 
showed that OBP-301 reduced the frequency of CD133+ cells, whereas cisplatin and 
irradiation increased compared with control (Fig. 5B).  
Next we visualized the treatment dynamics in established FUCCI-expressing MKN45 
tumor xenografts with or without OBP-301 infection (Supplementary Fig. S10B). 
FUCCI-expressing MKN45 tumors had the distribution of cancer cells in G0/ G1, S and G2/M 
phases (Fig. 5A). As tumor grew bigger, cancer cells in G0/ G1 phase increased (Fig. 5C and 
5D), indicating the existence of dormant cancer cells. After cisplatin or paclitaxel treatment, 
the tumor consisted mostly of red fluorescent cells (Fig. 5D), indicating that the cytotoxic 
agents killed only cycling cancer cells and had little effect on quiescent dormant cancer cells. 
These tumors re-grew with the quiescent cells re-entering the cell cycle 21 days after last 
treatment (Figs. 5D). In contrast, intratumor injection of OBP-301 mobilized the cancer cells 
into the S/G2/M-phase trap in vivo, leading to elimination of tumor cells at S/G2/M phases 
(Fig. 5D). These data indicate that OBP-301 could more efficiently kill quiescent CS-like 
cells in tumors by inducing cell-cycle progression. 
 
OBP-301 sensitizes quiescent cancer stem-like cells to chemotherapy by cell-cycle 
mobilization and S/G2/M-phase-trapping. 
 As we previously demonstrated that OBP-301 enhances the sensitivities to 
chemotherapeutic agents in various types of human cancer cells (30, 31), we further 
evaluated whether OBP-301 sensitizes quiescent CD133+ CS-like cells to chemotherapy by 
inducing cell cycle progression and S/G2/M-phase trapping. OBP-301 infection significantly 
enhanced the inhibitory effect of chemotherapy on the cell viability and tumor sphere 
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formation of CD133+ cells (Fig. 6A and Supplementary Fig. 13). Tumor spheres treated with 
chemotherapy and OBP-301 contained an increased percentage of tumor cells at G2/M phases 
compared to OBP-301 alone (Fig. 6B). The combination of OBP-301 and chemotherapy 
(Supplementary Fig. S10C) significantly suppressed the tumor growth compared to 
chemotherapy or OBP-301 alone (Fig. 6C and Supplementary Fig. S14). Cross-sections of 
tumor tissues demonstrated that combination of chemotherapy and OBP-301 induced an 
increased percentage of tumor cells at G2/M phases compared to OBP-301 alone (Fig. 6D). 
These results suggest that OBP-301 sensitizes the quiescent CS-like cells to 
chemotherapy-mediated G2/M arrest by inducing cell cycle progression and 
S/G2/M-phase-trapping. 
 
Discussion 
 
Here we have described that a bioengineered telomerase-specific oncolytic 
adenovirus, OBP-301, efficiently kills CD133+ CS-like cells that have higher telomerase 
activity through enhanced E1A-mediated cell-cycle mobilization and S-phase-trapping. By 
using FUCCI technology in combination with tumor-sphere culture, we visualized the virus 
penetration, the cell-cycle dynamics, and the subsequent elimination of quiescent CS-like 
cells in dormant tumor spheres (Supplementary Fig. S15A). 
CS-like cells have been shown to be highly resistant to chemotherapeutic agents (32, 
33) and ionizing radiation (24-26). As expected, CD133+ human gastric cancer cells were 
more resistant to conventional therapies than CD133− cells; OBP-301, however, efficiently 
reduced the viability of CD133+ cells as similar as CD133− cells. Moreover, we demonstrated 
that OBP-301 significantly reduced the stem cell properties of CD133+ cells in vitro and in 
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vivo compared with conventional chemoradiotherapy and further sensitized CD133+ CS-like 
cells to chemotherapy. These findings indicate that OBP-301 is a promising anticancer 
therapy to eliminate CS-like cells more efficiently than conventional therapy in the clinical 
setting. 
  Recent studies have showed that p53 and p21cip1/waf1 maintain the quiescent state in 
hematopoietic stem cells (34, 35). Moreover, p27kip1 has been suggested to be involved in 
suppression of the transition from the G0 phase to G1/S phases (36, 37). CS-like cells 
maintain a more quiescent state than non-CS-like cells, which is associated with CS-like cell 
resistance to conventional therapies (9, 10). OBP-301 induced S and G2/M phase entry and 
subsequent cell death in quiescent CD133+ cells through upregulation of E2F1-related 
proteins and downregulation of p53-related and p27 proteins in an E1A-dependent manner. A 
recent report suggested that suppression of the p53-mediated G1 checkpoint is required for 
E2F1-induced S phase entry (38). Furthermore, adenoviral E1A has been shown to suppress 
p53-mediated cell cycle arrest after DNA damage (39). Thus, OBP-301 can inhibit CS-like 
cells from maintaining quiescent state and enforce them into cell-cycling by not only 
upregulating E2F-related proteins, but also downregulating p53-related and p27 proteins 
(Supplementary Fig. S15B), leading to the sensitization to chemotherapy. 
FUCCI (23) is a powerful tool to visualize the quiescent state in CS-like cells and the 
treatment dynamics of OBP-301 against quiescent CS-like cells. When tumor spheres were 
formed, CD133+ cells maintained a quiescent state, which was defined by the red fluorescent 
nuclei expressed in G0/ G1 phases. In contrast, S and G2/M phase entry induced by OBP-301 
could be clearly visualized as yellow and green fluorescent nuclei, respectively. Our data 
indicate that three-dimensional cultures are extremely important for the maintenance of the 
quiescence of CD133+ cells. FUCCI-based real-time imaging of the cell-cycle provides a 
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platform for the screening of candidate therapeutic agents that modulate the quiescent state of 
drug-resistant CS-like cells.  
In conclusion, we have clearly demonstrated that a genetically engineered oncolytic 
adenovirus, OBP-301, efficiently eradicates quiescent CS-like cells in solid tumors by 
cell-cycle mobilization and S/G2/M-phase-trapping. A phase I clinical trial of intratumoral 
injection of OBP-301 in patients with advanced solid tumors recently completed and 
OBP-301 monotherapy was well tolerated by these patients (20). However, the adenoviral 
delivery to inaccessible primary and metastatic tumor tissues is a major obstacle for clinical 
translation of this treatment modality. In this study, the combination therapy of OBP-301 with 
chemotherapy was highly effective antitumor therapy to eliminate both CS-like and 
non-CS-like cells in a xenograft model. Future clinical trials of intratumoral injection of 
OBP-301 in combination with conventional antitumor therapy are suggested by the results of 
the present study. 
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Figure Legends 
 
Fig. 1 CD133+ cancer stem-like cells in human gastric cancer exhibit CS-like cell 
properties and are more quiescent.  
A, Flow cytometric analysis of CD133 expression in parental (P) and radioresistant 
(R) MKN45 cells. Representative dot plots (left) and data from five experiments (right) are 
shown. B, CD133+ MKN45 cancer cells exhibit CS-like properties. Representative image of 
colonies from CD133+ or CD133– cells. Histogram shows the size of colonies from CD133+ 
or CD133– cells (left). Quantitative measurement of the tumor sphere-forming potential of 
CD133+ and CD133− cells (middle). Representative image of tumor spheres derived from 
CD133+ and CD133− cells. Histogram shows the numbers of tumor spheres from CD133+ or 
CD133− cells. Scale bars, 500 μm. Tumorigenicities of CD133+ and CD133− cells in 
immunodeficient NOD/SCID mice (right). Growth curve of each tumors and representative 
photograph are shown. C, Cell viability of CD133+ and CD133− cells from radioresistant 
MKN45 cells to 5-fluorouracil, cisplatin, paclitaxel and irradiation. D, Time-lapse imaging of 
CD133+ and CD133− cells from radioresistant MKN45 cells expressing cell cycle-dependent 
fluorescent proteins (FUCCI) (upper). The cells in G0/ G1, S, or G2/M phases appear red, 
yellow, or green, respectively. Histogram shows the cell cycle phase of FUCCI-expressing 
CD133+ and CD133− cells cultured for 48 hours after sorting (lower right). The percentage of 
cells in G0/ G1, S, and G2/M phases are shown. Cell proliferation rate of CD133+ and CD133− 
cells (lower left). Scale bars, 50 μm. Data are shown as means ± SD (n = 5). *P < 0.01. 
 
Fig. 2 OBP-301 lethally induces S phase transition of quiescent CD133+ cancer 
stem-like cells with decreasing CS-like cell frequency via enhanced viral replication.  
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A, OBP-301 efficiently kills CD133+ CS-like cells. Cell viability of CD133+ and 
CD133− cells from MKN45 cells to OBP-301 infection. (left). The percentages of CD133+ 
cells in radioresistant MKN45 cells treated with OBP-301, cisplatin, or radiation were 
analyzed by flow cytometry (right). B, OBP-301 can replicate more in CD133+ that have 
more activity of hTERT than in CD133− cells. Expression of hTERT mRNA in CD133+ and 
CD133− MKN45 cells assessed by quantitative real-time RT-PCR (qRT-PCR) (upper left). 
The relative levels of hTERT mRNA were calculated after normalization with reference to the 
expression of PBGD mRNA. Expression of E1A mRNA in CD133+ and CD133−MKN45 
cells after OBP-301 infection at an MOI of 10 PFU/cell for 2 hours. Expression of E1A 
mRNA was analyzed over the following 3 days qRT-PCR (upper middle). The relative levels 
of E1A mRNA were calculated after normalization with reference to the expression of 
GAPDH mRNA. Western blot analysis of E1A expression in CD133+ and CD133− MKN45 
cells treated with OBP-301 for 48 hours (lower left). Quantitatively relative expression level 
of E1A protein, normalized to b-actin, using NIH ImageJ software (lower left). Quantitative 
measurement of viral DNA replication in CD133+ and CD133− MKN45 cells after OBP-301 
infection at an MOI of 10 PFU/cell for 2 hours (lower right). E1A copy number was analyzed 
over the following 3 days using qPCR. C, Time-lapse imaging of FUCCI-expressing CD133+ 
and CD133− cells treated with OBP-301 at an MOI of 20 PFU/cell. The cells in G0/ G1, S, or 
G2/M phases appear red, yellow, or green, respectively. Histogram shows the cell cycle 
phases of FUCCI-expressing CD133+ and CD133− cells treated with OBP-301 for 48 hours. 
The percentage of cells in G0/ G1, S, and G2/M phases are shown. D, Western blot analysis of 
E2F1, c-Myc, phospho-Akt, Akt, p53, p21 and p27 expression in CD133+ cells treated with 
OBP-301, cisplatin, or radiation for 48 hours. β-actin was assayed as a loading control for all 
experiments. Data are shown as means ± SD (n = 5). *P < 0.05, **P < 0.01. 
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Fig. 3 Three-dimensional tumor spheres maintain CD133+ cells by arresting the cell 
cycle.  
A, Time-lapse images of FUCCI-expressing CD133+ cells in three-dimensional culture 
without serum. Purified FUCCI-expressing CD133+ cells were cultured on agar in serum-free 
medium containing EGF and bFGF for 48 hours (upper). The cells in G0/ G1, S, or G2/M 
phases appear red, yellow, or green, respectively. Histogram shows the cell cycle phase of 
FUCCI-expressing CD133+ cells in three-dimensional culture without serum (lower). The 
percentage of cells in G0/ G1, S, and G2/M phases are shown. B, Representative image of 
tumor spheres from FUCCI-expressing CD133+ and CD133− cells (upper). Histogram shows 
the cell cycle phase of tumor spheres from FUCCI-expressing CD133+ and CD133− cells 
(lower). C, Time-lapse images of FUCCI-expressing CD133+ cells in monolayer culture or 
FUCCI-expressing tumor spheres in three-dimensional culture without serum (3D without 
serum) or tumor spheres in monolayer culture with serum (monolayer culture) (upper). 
Histogram shows the cell cycle phase of FUCCI-expressing CD133+ cells in 2D culture, 
FUCCI-expressing established tumor spheres in 3D without serum, or tumor sphere in 
monolayer culture with serum (monolayer culture) (lower). D, Comparison of changes in 
CD133+ positive ratio of CD133+ cells in monolayer culture, tumor spheres in 3D culture 
without serum, or with serum. Representative dot plots (left) and data from three experiments 
(right) are shown. Data are shown as means ± SD (n = 5). *P < 0.01. Scale bars, 500 μm. 
 
Fig. 4 Visualization of eliminating dormant tumor spheres by virus infection. 
A, Time-lapse images of tumor spheres treated with OBP-301 (5 × 106 PFU), 
cisplatin (10 μM), or radiation (10 Gy). The cells in G0/ G1, S, or G2/M phases appear red, 
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yellow, or green, respectively. B, Histogram shows the cell cycle phase of the spheres with 
OBP-301, cisplatin, or radiation. The percentage of cells in G0/ G1, S, and G2/M phases are 
shown. C, Representative image of control, OBP-301, cisplatin, or radiation treated spheres 
(upper). Histogram shows that relative cell viability of treated tumor spheres (lower). D, The 
CD133+ tumor spheres treated as above were stained for E2F1, phospho-Akt, p53, and p21. 
Immuofluorescent staining was visualized by confocal laser microscopy. Scale bars, 100 μm. 
Data are shown as means ± SD (n = 5). *P < 0.01. 
 
Fig. 5 OBP-301 induces cell-cycle progression and efficiently kills dormant cancer cells 
resistant to conventional therapy in established human tumor xenografts.  
CD133+ rich radioresistant MKN45 cells (5 × 106 cells/mouse) were injected 
subcutaneously into the left flanks of mice. When the tumors reached approximate 6 mm in 
diameter (tumor volume, 100-120 mm3), mice were administered OBP-301 intratumorally (1 
× 108 PFU/tumor), injected intraperitoneally with cisplatin (4mg/kg), or exposed to 2Gy of 
radiation for three cycles every 3 days. A, The growth curves of tumors derived from 
radioresistant MKN45 cells after treatment with OBP-301, cisplatin or radiation. Black 
arrows indicate the day of treatment. B, Expression of CD133 mRNA in tumors treated with 
OBP-301, cisplatin or radiation at 1, 2 and 3 weeks after treatment (upper). Representative 
image of CD133-stained tumor section treated with OBP-301, cisplatin, or radiation (lower 
left). Scale bars, 100 μm. Histogram shows the percentages of CD133+ cells in vivo tumor 
treated with OBP-301, cisplatin, or radiation (lower right). The percentage of CD133+ cells 
were calculated by dividing the number of CD133+ cells by the total number of cells. Data are 
shown as means ± SD (n = 3). *P < 0.05. C, D, FUCCI-expressing MKN45 cells (5 × 106 
cells/mouse) were injected subcutaneously into the left flanks of mice. When the tumors 
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reached approximately approximate 7 mm in diameter (tumor volume, 150-180 mm3), mice 
were administered OBP-301 intratumorally (1 × 108 PFU/tumor), injected intraperitoneally 
with cisplatin (4mg/kg) or paclitaxel (5mg/kg) for three cycles every 3 days. Representative 
images of cross-sections of FUCCI-expressing MKN45 subcutaneous tumor of control, 
OBP-301, cisplatin, or paclitaxel treated mice (left). The cells in G0/ G1, S, or G2/M phases 
appear red, yellow, or green, respectively. Histogram shows the cell cycle phase of 
FUCCI-expressing MKN45 subcutaneous tumor from control, OBP-301, cisplatin, or 
paclitaxel treated mice (right). The percentage of cells in G0/ G1, S, and G2/M phases are 
shown. Data are shown as means ± SD (n = 5). *P < 0.05. Scale bars, 500μm. 
 
Fig. 6 OBP-301 sensitizes quiescent CD133+ CS-like cells to chemotherapy by inducing 
cell-cycle progression. 
A, Representative image of tumor spheres from FUCCI-expressing CD133+ cells after 
treatment with cisplatin, paclitaxel, OBP-301 and the combination of OBP-301 and 
chemotherapy (upper). The cells in G0/ G1, S, or G2/M phases appear red, yellow, or green, 
respectively. The area of tumor sphere was calculated using NIH ImageJ software (lower). 
Data are shown as means ± SD (n = 5). *P < 0.05. Scale bars, 500 μm. B, Histogram shows 
the cell cycle phase of tumor spheres from FUCCI-expressing CD133+ cells after treatment 
with chemotherapy, OBP-301 and the combination of OBP-301 and chemotherapy. The 
percentage of cells in G0/ G1, S, and G2/M phases are shown. Data are shown as means ± SD 
(n = 5). *P < 0.05. C, FUCCI-expressing MKN45 cells (5 × 106 cells/mouse) were injected 
subcutaneously into the left flanks of mice. When the tumors reached approximately about 8 
mm in diameter (tumor volume, 300 mm3), mice were administered OBP-301 intratumorally 
(1 × 108 PFU/tumor), injected intraperitoneally with cisplatin (4mg/kg) or paclitaxel 
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(5mg/kg) for five cycles every 3 days. The growth curves of tumors derived from 
FUCCI-expressing MKN45 cells after treatment with chemotherapy, OBP-301 or the 
combination of OBP-301 and chemotherapy (left). Red and green arrows indicate the day of 
treatment with OBP-301 and chemotherapy, respectively. Macroscopic photographs of 
FUCCI-expressing tumors of control, treated with OBP-301, cisplatin, paclitaxel or the 
combination of OBP-301 and chemotherapy (right). Scale bars, 10 mm. D, Representative 
image of cross-sections of FUCCI-expressing MKN45 subcutaneous tumor of control, 
OBP-301, cisplatin, paclitaxel or the combination of OBP-301 and chemotherapy treated 
mice (upper). Histogram shows cell cycle phase of FUCCI-expressing MKN45 subcutaneous 
tumor of control, treated with OBP-301, cisplatin, paclitaxel or the combination of OBP-301 
and chemotherapy (lower). Data are shown as means ± SD (n = 6). *P < 0.05, ANOVA. Scale 
bars, 500μm. 
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